SCHEMBL6743325

SCHEMBL6743325

N#CCNC(=O)C(CNC(=O)c1ccccc1)S(=O)(=O)Cc1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CTSL P07711 8/20 0.54
CTSS P25774 7/20 0.54
CTSB P07858 3/20 0.54
CTSV O60911 2/20 0.54
NAMPT P43490 1/20 0.48
CTSK P43235 1/20 0.48
GAA P10253 1/20 0.48
ALDH1A1 P00352 2/20 0.46
LMNA P02545 2/20 0.46
HTT P42858 2/20 0.46
MAPT P10636 1/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
NPC1 O15118 1/20 0.46
RAB9A P51151 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
TDP1 Q9NUW8 1/20 0.45
NPSR1 Q6W5P4 1/20 0.44
CA2 P00918 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6061910 0.89 CTSL (0.56) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6741252 0.88 CTSL (0.51) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6740671 0.88 CTSL (0.51) CTSLCTSSCTSBCTSVCTSK
SCHEMBL7654250 0.84 CTSL (0.52) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6737517 0.82 CTSL (0.49) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6741968 0.82 CTSL (0.54) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6739753 0.82 CTSB (0.62) CTSLCTSSCTSBCTSVCTSK
SCHEMBL6744955 0.82 CTSL (0.46) CTSLCTSSCTSBCTSKALDH1A1
SCHEMBL6837983 0.81 CTSB (0.55) CTSLCTSSCTSBCTSVCTSK
SCHEMBL7666762 0.81 CTSL (0.48) CTSLCTSSCTSBCTSVCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors AXYS PHARMACEUTICALS, INC. 2004-01-22 US disclosed
US-6492362-B1 Compounds and compositions as cathepsin S inhibitors AXYS PHARMACEUTICALS, INC. 2002-12-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014796-A1 Novel compounds and compositions as cathepsin S inhititors CTSS, CTSB, CTSE CTSL 10/4885CTSS 1/4885CTSB 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.